BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 18495732)

  • 1. Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
    Cañete JD; Celis R; Moll C; Izquierdo E; Marsal S; Sanmartí R; Palacín A; Lora D; de la Cruz J; Pablos JL
    Ann Rheum Dis; 2009 May; 68(5):751-6. PubMed ID: 18495732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study.
    Klaasen R; Thurlings RM; Wijbrandts CA; van Kuijk AW; Baeten D; Gerlag DM; Tak PP
    Arthritis Rheum; 2009 Nov; 60(11):3217-24. PubMed ID: 19877042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients.
    van der Pouw Kraan TC; Wijbrandts CA; van Baarsen LG; Rustenburg F; Baggen JM; Verweij CL; Tak PP
    Ann Rheum Dis; 2008 Apr; 67(4):563-6. PubMed ID: 18042642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ectopic lymphoid neogenesis in psoriatic arthritis.
    Cañete JD; Santiago B; Cantaert T; Sanmartí R; Palacin A; Celis R; Graell E; Gil-Torregrosa B; Baeten D; Pablos JL
    Ann Rheum Dis; 2007 Jun; 66(6):720-6. PubMed ID: 17223654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
    Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
    Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synovial lymphoid neogenesis does not define a specific clinical rheumatoid arthritis phenotype.
    Thurlings RM; Wijbrandts CA; Mebius RE; Cantaert T; Dinant HJ; van der Pouw-Kraan TC; Verweij CL; Baeten D; Tak PP
    Arthritis Rheum; 2008 Jun; 58(6):1582-9. PubMed ID: 18512774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
    Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PL; Nordström DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF
    Ann Rheum Dis; 2011 Sep; 70(9):1575-80. PubMed ID: 21571731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synovial fibroblast hyperplasia in rheumatoid arthritis: clinicopathologic correlations and partial reversal by anti-tumor necrosis factor therapy.
    Izquierdo E; Cañete JD; Celis R; Del Rey MJ; Usategui A; Marsal S; Sanmartí R; Criado G; Pablos JL
    Arthritis Rheum; 2011 Sep; 63(9):2575-83. PubMed ID: 21547893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
    van Oosterhout M; Levarht EW; Sont JK; Huizinga TW; Toes RE; van Laar JM
    Ann Rheum Dis; 2005 Apr; 64(4):537-43. PubMed ID: 15769913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
    Quartuccio L; Fabris M; Salvin S; Atzeni F; Saracco M; Benucci M; Cimmino M; Morassi P; Masolini P; Pellerito R; Cutolo M; Puttini PS; De Vita S
    Rheumatology (Oxford); 2009 Dec; 48(12):1557-9. PubMed ID: 19789202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synovial expression of IL-15 in rheumatoid arthritis is not influenced by blockade of tumour necrosis factor.
    Ernestam S; af Klint E; Catrina AI; Sundberg E; Engström M; Klareskog L; Ulfgren AK
    Arthritis Res Ther; 2006; 8(1):R18. PubMed ID: 16507118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation.
    Teng YK; Levarht EW; Toes RE; Huizinga TW; van Laar JM
    Ann Rheum Dis; 2009 Jun; 68(6):1011-6. PubMed ID: 18647852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
    Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM
    Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
    Rioja I; Hughes FJ; Sharp CH; Warnock LC; Montgomery DS; Akil M; Wilson AG; Binks MH; Dickson MC
    Arthritis Rheum; 2008 Aug; 58(8):2257-67. PubMed ID: 18668547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour necrosis factor alpha (TNF-alpha) interferes with Fas-mediated apoptotic cell death on rheumatoid arthritis (RA) synovial cells: a possible mechanism of rheumatoid synovial hyperplasia and a clinical benefit of anti-TNF-alpha therapy for RA.
    Ohshima S; Mima T; Sasai M; Nishioka K; Shimizu M; Murata N; Yoshikawa H; Nakanishi K; Suemura M; McCloskey RV; Kishimoto T; Saeki Y
    Cytokine; 2000 Mar; 12(3):281-8. PubMed ID: 10704256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue.
    Smeets TJ; Kraan MC; van Loon ME; Tak PP
    Arthritis Rheum; 2003 Aug; 48(8):2155-62. PubMed ID: 12905468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-TNF-alpha agents are less effective for the treatment of rheumatoid arthritis in current smokers.
    Abhishek A; Butt S; Gadsby K; Zhang W; Deighton CM
    J Clin Rheumatol; 2010 Jan; 16(1):15-8. PubMed ID: 20051749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synovial vascular patterns and angiogenic factors expression in synovial tissue and serum of patients with rheumatoid arthritis.
    Salvador G; Sanmartí R; Gil-Torregrosa B; García-Peiró A; Rodríguez-Cros JR; Cañete JD
    Rheumatology (Oxford); 2006 Aug; 45(8):966-71. PubMed ID: 16490752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis.
    Vos K; Thurlings RM; Wijbrandts CA; van Schaardenburg D; Gerlag DM; Tak PP
    Arthritis Rheum; 2007 Mar; 56(3):772-8. PubMed ID: 17328049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.